CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating activities
Net (loss) income	$ (51,969,323)	$ (42,221,497)	$ 4,097,849
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Bad debt expense	1,082,920	870,715	578,805
Depreciation	3,885,688	5,566,184	6,790,677
Amortization	2,294,077	3,381,743	3,493,408
Impairment charges	6,400,000	54,132,407	0
Loss on early extinguishment and modification of debt	1,419,010	81,503	0
Deferred income tax expense (benefit)	45,900,296	(18,520,360)	3,052,909
Amortization of debt issuance costs	233,256	605,558	913,509
Equity compensation	2,099,941	2,594,523	2,895,012
Gain on sale of clinical trial services business	(3,968,714)	0	0
Debt financing costs	0	279,005	0
Other noncash costs	11,890	543,296	22,832
Changes in operating assets and liabilities:
Accounts receivable	2,036,387	(4,255,411)	(7,973,162)
Prepaid expenses and other assets	(1,847,999)	(444,351)	1,878,943
Income taxes	(138,401)	1,748,750	4,310,626
Accounts payable and accrued expenses	(319,856)	4,128,000	(1,327,040)
Other liabilities	1,539,840	1,656,065	(438,168)
Net cash provided by operating activities	8,659,012	10,146,130	18,296,200
Investing activities
Proceeds from sale of business segment, net of cash sold and transaction costs	45,655,319	0	0
Acquisition of assets of On Assignment, Inc.	(28,700,000)	0	0
Purchases of property and equipment	(1,750,663)	(2,218,877)	(3,998,129)
Liquidation of foreign cash investments	0	2,652,335	0
Other investing activities	0	(258,832)	(197,907)
Net cash provided by (used in) investing activities	15,204,656	174,626	(4,196,036)
Financing activities
Debt issuance costs	(505,905)	(1,377,410)	0
Repurchase of stock for tax withholdings	(300,531)	(152,430)	(221,596)
Stock repurchase and retirement	0	(374,248)	(2,234,585)
Proceeds from borrowing on term loan	0	25,000,000	0
Principal payments on term loan	(23,125,000)	(43,326,056)	(14,088,284)
Borrowings under revolving credit facility	0	26,900,000	2,500,000
Repayments on revolving credit facility	(10,000,000)	(16,900,000)	0
Borrowings under asset-based revolving credit facility	63,444,175	0	0
Repayments on asset-based revolving credit facility	(55,044,175)	0	0
Repayments of capital lease obligations and note payable	(529,884)	(352,776)	(191,755)
Net cash used in financing activities	(26,061,320)	(10,582,920)	(14,236,220)
Effect of exchange rate changes on cash	(210,427)	76,821	(172,573)
Change in cash and cash equivalents	(2,408,079)	(185,343)	(308,629)
Cash and cash equivalents at beginning of year	10,462,692	10,648,035	10,956,664
Cash and cash equivalents at end of year	8,054,613	10,462,692	10,648,035
Supplemental disclosure of noncash investing and financing activities:
Equipment purchased through capital lease obligations	0	302,316	312,562
Insurance premium financing	0	189,654	0
Supplemental disclosure of cash flow information:
Interest paid	621,969	1,467,233	2,134,575
Income taxes paid	1,164,472	1,681,992	1,559,424
Income tax refunds	$ (322,512)	$ (564,430)	$ (4,792,495)